AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23839484
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg co-administered with bosutinib 400 mg
Trial: 23839484
Drug: Bosutinib 400
RxNorm normalized name: bosutinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 400 mg alone
Trial: 23840618
Drug: MVA85A vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA85A vaccine (first dose) in ART naïve subjects
Trial: 23840618
Drug: MVA85A vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA85A vaccine (second dose) in ART naïve subjects
Trial: 23840618
Drug: MVA85A vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA85A vaccine (first dose) in subjects on ART
Trial: 23840618
Drug: MVA85A vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA85A vaccine (two doses) in ART naïve subjects
Trial: 23841031
Drug: Rigosertib (ON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigosertib (ON 01910.Na) administered as a 3-day continuous infusion every 2 weeks at escalating doses (50, 100, 150, 250, 325, 400, 650, 850, 1,050, 1,375, 1,700 mg/m(2)/24h).
Trial: 23845947
Drug: Lentiviral gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lentiviral gene therapy using a lentiviral vector encoding functional WASP
Trial: 23845948
Drug: Lentiviral gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lentiviral gene therapy using a lentiviral vector to transfer a functional ARSA gene into hematopoietic stem cells (HSCs)
Trial: 23846776
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral dose of dabrafenib
Trial: 23846776
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) microdose of 50 µg radiolabeled dabrafenib
Trial: 23847271
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (endoscopic therapy combined with non-selective β-blockers and anticoagulants)
Trial: 23850908
Drug: Successful cardioversion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful cardioversion without anticoagulation or peri-procedural heparin therapy
Trial: 23851911
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice daily plus Darunavir/Ritonavir 800/100 mg once daily
Trial: 23855804
Drug: Cetuximab administered
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab administered as loading dose and then weekly during radiotherapy (exact dosage not specified)
Trial: 23855804
Drug: Intensity-modulated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiation therapy (IMRT) or 3D-dimensional radiation therapy
Trial: 23856024
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for inherited surfactant metabolism disorders (specific treatment details not provided)
Trial: 23856681
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of alternate-day aspirin
Trial: 23857959
Drug: Sepantronium Bromide
RxNorm normalized name: Potassium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sepantronium Bromide (10 mg/m(2)/day, continuous intravenous infusion over 72 hours)
Trial: 23857959
Drug: Carboplatin (AUC6)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (AUC6) and Paclitaxel (200 mg/m(2))
Trial: 23857966
Drug: Pazopanib (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (tablet formulation) administered once daily in 28-day cycles at four dose levels (275 to 600 mg/m(2))
Trial: 23857966
Drug: Pazopanib (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (tablet formulation)
Trial: 23860199
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate 400 mg per day for 1 year
Trial: 23860535
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m², Carboplatin AUC 5 mg/ml/min, Bevacizumab 15 mg/kg every 21 days for six cycles followed by maintenance Bevacizumab
Trial: 23860537
Drug: Lenvatinib 4
RxNorm normalized name: lenvatinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 4 mg BID with carboplatin/paclitaxel
Trial: 23860537
Drug: Lenvatinib 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 6 mg BID with carboplatin/paclitaxel
Trial: 23861180
Drug: Citalopram (SSRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (SSRI treatment)
Trial: 23861248
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m² IV) administered at 3, 6, 9, and 12 months after transplantation
Trial: 23863898
Drug: Reinduction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinduction therapy followed by alloHSCT
Trial: 23866828
Drug: Everolimus 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 1.5 mg/day + reduced-dose cyclosporine
Trial: 23866828
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2 g/day + standard dose cyclosporine
Trial: 23867211
Drug: Denosumab 120
RxNorm normalized name: DENOSUMAB 120 MG/1.7 ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 120 mg subcutaneously every 4 weeks with loading doses on days 8 and 15 of the first cycle (for cohorts 1 and 2)
Trial: 23867211
Drug: Denosumab 120
RxNorm normalized name: DENOSUMAB 120 MG/1.7 ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 120 mg subcutaneously every 4 weeks with loading doses on days 8 and 15 of the first cycle (for cohort 2)
Trial: 23867776
Drug: ROTEM analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROTEM analysis at T1 (10 min after heparin administration)
Trial: 23868427
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of HPPH (4.0 mg/m2), followed by activation with 665-nm laser light in the surgical bed immediately after tumor resection.
Trial: 23870704
Drug: Maribavir (MBV)
RxNorm normalized name: maribavir
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir (MBV) 400 mg p.o. twice per day
Trial: 23872668
Drug: Allogeneic mesenchymal
RxNorm normalized name: Allogeneic mesenchymal precursor cell
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic mesenchymal stromal cells (MSCs) administered intravenously at a dosage of 2 × 10(6) cells/kg body weight weekly for 4 weeks.
Trial: 23876210
Drug: Entecavir (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir (0.5 or 1.0 mg)
Trial: 23878115
Drug: Lapatinib (500-1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (500-1500 mg/day) + Docetaxel (triweekly; 60-100 mg/m²) + Trastuzumab (weekly; 2 mg/kg fixed dose)
Trial: 23878140
Drug: FLT3 N676K
RxNorm normalized name: Pim/flt3 kinase inhibitor sel24
DrugBank: SEL-24 (DB18082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLT3 N676K mutation with concurrent FLT3-ITD
Trial: 23879405
Drug: sorafenib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib (2 x 400 mg/day orally) and pegylated interferon alpha-2b (3 μg/kg body weight 1 x/week subcutaneously)
Trial: 23880820
Drug: PEP02 (MM-398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEP02 (MM-398) 120 mg/m(-2) intravenous injection every 3 weeks
Trial: 23881401
Drug: Proceed™ Ventral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proceed™ Ventral Patch (PVP™)
Trial: 23883872
Drug: Intravenous tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tigecycline (100 mg for 30 min)
Trial: 23886346
Drug: Cilostazol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (50 mg for 2 weeks, 100 mg for 6 weeks)
Trial: 23887852
Drug: Sorafenib 200
RxNorm normalized name: sorafenib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 200 mg twice daily and Bortezomib 1.3 mg/m2 on days 1, 4, 8, 11 (21-day cycles)
Trial: 23887852
Drug: Sorafenib 200
RxNorm normalized name: sorafenib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 200 mg twice daily and Bortezomib 1 mg/m2 on days 1, 4, 8, 11 (21-day cycles)
Trial: 23890349
Drug: Dietary protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary protein intake (0.98 ± 0.28 g/kg body weight in males; 0.95 ± 0.29 g/kg body weight in females)
Trial: 23890998
Drug: High platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High platelet reactivity on aspirin
Trial: 23891361
Drug: Ticagrelor (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (in addition to aspirin)
Trial: 23891361
Drug: Clopidogrel (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (in addition to aspirin)
Trial: 23892959
Drug: AZD7762 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7762 monotherapy (6 mg, 9 mg, 21 mg, 30 mg)
Trial: 23892959
Drug: AZD7762 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7762 plus gemcitabine (1,000 mg/m2)
Trial: 23892959
Drug: AZD7762 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7762 monotherapy
Trial: 23892959
Drug: AZD7762 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7762 (all doses)
Trial: 23893090
Drug: Ranibizumab (Lucentis)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (Lucentis) 0.5 mg/0.05 ml injections
Trial: 23893090
Drug: Ranibizumab (Lucentis)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (Lucentis) injections
Trial: 23894304
Drug: Irinotecan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 50 mg/m(2)/day for 5 days combined with vincristine 1.5 mg/m(2) on days 1 and 8, temozolomide 100 mg/m(2) on days 1-5, and bevacizumab 15 mg/kg on day 1, administered every 21 days for a maximum of 12 cycles
Trial: 23894304
Drug: Irinotecan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 50 mg/m(2)/day for 5 days
Trial: 23896965
Drug: Eltrombopag (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (12.5, 25, or 50 mg once daily)
Trial: 23898383
Drug: PBMCs from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMCs from IBS children cultured with 5 ng/mL LPS
Trial: 23898383
Drug: PBMCs from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMCs from healthy controls (HCs) cultured with 5 ng/mL LPS
Trial: 23899439
Drug: DTG 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG 50 mg daily for 5-7 days
Trial: 23900652
Drug: Biofeedback (BF)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biofeedback (BF) alone or in combination with electrical stimulation (ES)
Trial: 23901077
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine delivered on alternative dosing schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months)
Trial: 23901077
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine delivered on the 0, 12, 24 month schedule
Trial: 23901077
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine delivered on any of the alternative dosing schedules
Trial: 23901077
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HPV vaccine delivered at 0 and 12 months
Trial: 23903369
Drug: Tolvaptan (90/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (90/30 mg/day, split dose) for 3 weeks
Trial: 23903369
Drug: Tolvaptan (90/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (90/30 mg/day, split dose)
Trial: 23903897
Drug: Icrucumab (2-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icrucumab (2-12 mg/kg weekly, 15 mg/kg every other week, 20 mg/kg every third week)
Trial: 23904461
Drug: TriMixDC-MEL (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TriMixDC-MEL (intravenous synthetic mRNA electroporated dendritic cell immunotherapy)
Trial: 23905663
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of strength training and endurance training (n = 30)
Trial: 23905663
Drug: Careful treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Careful treatment including diet and physical recommendations (n = 29)
Trial: 23907406
Drug: Azacitidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (75 mg/m² for 5 days), Valproic Acid (20 mg/kg for 7 days), Carboplatin (AUC 3.0 starting in second cycle)
Trial: 23907471
Drug: Clinical worsening
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical worsening (defined as worsening functional class, a ≥ 15% reduction in 6-min walk distance, all-cause hospitalization, or introduction of parenteral prostacyclin analog therapy)
Trial: 23907731
Drug: Serum B-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum B-type natriuretic peptide (BNP) test with a cutoff of >364 pg/mL
Trial: 23907731
Drug: Serum B-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum B-type natriuretic peptide (BNP) test with a cutoff of ≤ 182 pg/mL
Trial: 23907766
Drug: Vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine sulfate liposome injection (VSLI) at a maximum tolerated dose of 2.25 mg/m² once per week without a dose cap
Trial: 30239252
Drug: Vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine sulfate liposome injection (VSLI)
Trial: 23909727
Drug: Omega-3 polyunsaturated
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 polyunsaturated fatty acids (PUFA) added to parenteral nutrition
Trial: 23912473
Drug: Tapentadol prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol prolonged release (PR; 50-250 mg twice daily)
Trial: 23912473
Drug: Tapentadol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol treatment
Trial: 23912587
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with whole leukemia cells (up to 6 vaccines initiated between days 30 and 45 after transplantation)
Trial: 23912763
Drug: Anti-inflammatory strategies
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory strategies tested on the graft ex vivo during islet culture and/or on the graft site in vivo early after islet infusion.
Trial: 23915500
Drug: AA homozygotes
RxNorm normalized name: HOMOZYGOUS YUCATAN MINIATURE PIG ATAXIA TELANGIECTASIA MUTATED (ATM) GENE DISRUPTED BY A ATM-NEO RDNA CONSTRUCT IN EXON 57
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA homozygotes of rs2906569 (minor allele G, alternate allele A) at intron 1
Trial: 23915500
Drug: CC homozygotes
RxNorm normalized name: HOMOZYGOUS YUCATAN MINIATURE PIG ATAXIA TELANGIECTASIA MUTATED (ATM) GENE DISRUPTED BY A ATM-NEO RDNA CONSTRUCT IN EXON 57
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC homozygotes of rs2301963 (minor allele A, alternate allele C) at exon 3
Trial: 23917460
Drug: CYP phenotyping
RxNorm normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP phenotyping cocktail (50 mg tramadol, 20 mg omeprazole, 25 mg losartan, 200 mg caffeine) administered as a single oral dose.
Trial: 23921878
Drug: Ultra low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ultra low-dose OCP (1.0 mg norethindrone acetate and 10 micrograms ethinyl E2)
Trial: 23924590
Drug: 2010/11 seasonal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2010/11 seasonal, trivalent influenza vaccine (TIV)
Trial: 23924590
Drug: AS03 adjuvanted
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03 adjuvanted H1N1 vaccine
Trial: 23924602
Drug: Exocrine pancreatic
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exocrine pancreatic insufficiency (EPI) defined by FE-1 concentration <200 μg/g
Trial: 23924602
Drug: Severe exocrine
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe exocrine pancreatic insufficiency (EPI) defined by FE-1 concentration <100 μg/g
Trial: 23924639
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy sequencing after cessation of breastfeeding
Trial: 23928873
Drug: Discontinuation rate
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation rate
Trial: 23929075
Drug: Hypo-osmolar 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypo-osmolar 0.1% riboflavin solution
Trial: 23929075
Drug: Iso-osmolar 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iso-osmolar 0.1% riboflavin solution
Trial: 23929075
Drug: Post-treatment monitoring
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment monitoring
Trial: 23929949
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (1.35 × 10(5) PfSPZ), 5 doses
Trial: 23929949
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (1.35 × 10(5) PfSPZ), 4 doses
Trial: 23930209
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Trial: 23930209
Drug: Everolimus 7.5
RxNorm normalized name: everolimus 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 7.5 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Trial: 23930209
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Trial: 23932335
Drug: Double negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double negative for oestrogen- and progesterone receptors (ER/PR loss)
Trial: 23932458
Drug: Asthma Control
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asthma Control Questionnaire (ACQ) administered at 8 visits
Trial: 23938372
Drug: Staging laparoscopy
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staging laparoscopy (S-LPS) before primary debulking surgery (PDS) or neoadjuvant treatment (NACT)
Trial: 23939283
Drug: Dose-dense ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-dense ixabepilone (40 mg/m2 every 14 days with granulocyte-colony stimulating factor)
Trial: 23939283
Drug: Dose-dense FEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense FEC (5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2, cyclophosphamide 600 mg/m2 every 14 days with granulocyte-colony stimulating factor)
Trial: 23939368
Drug: Oral Rapid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Rapid Test (ORT)
Trial: 23939898
Drug: Voriconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (400 mg every 12 h on day 1, followed by 200 mg every 12 h for 3 days)
Trial: 23940128
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human PRL (r-hPRL) 60 μg/kg every 12 hours for 17 days
Trial: 23942767
Drug: MVD and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVD and CAD alone or in combination with PAH
Trial: 23945372
Drug: Larger ex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger ex vivo capsules in baseline CSF